Evicenter
Opdivo (nivolumab) in Metastatic non-small cell lung cancer
Manufacturer
Bristol-Myers Squibb Company
Prescribing information
Opdivo (opens in a new tab)
Questions
60
Last updated

All questions

Clinical trials: Opdivo (nivolumab) in metastatic non-small cell lung cancer

15 questions · 4 sources

Study results

Does Opdivo plus Yervoy help patients live longer than chemotherapy (Checkmate 227)?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.

What was progression-free survival with Opdivo plus Yervoy in Checkmate 227?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.

What response rate did Opdivo plus Yervoy achieve in Checkmate 227?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.

Does Opdivo plus Yervoy and chemo improve survival (Checkmate 9LA)?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

Does Opdivo plus Yervoy and chemotherapy delay progression (Checkmate 9LA)?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

What response rate did Opdivo plus Yervoy and chemotherapy achieve (Checkmate 9LA)?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

What response rates did Opdivo achieve vs docetaxel in previously treated NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

What was progression-free survival with Opdivo vs docetaxel in previously treated NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

Note: The first result is from Checkmate 057 (non-squamous) and the second from Checkmate 017 (squamous), as labeled on the efficacy page.

Clinical trials

How was the Opdivo plus Yervoy Checkmate 227 trial designed?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

How was the Checkmate 9LA trial of Opdivo, Yervoy, and chemotherapy designed?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

How were the Opdivo Checkmate 057 and 017 trials designed?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

What evidence supports Opdivo Qvantig for previously treated metastatic NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

Note: Checkmate 67T enrolled adults with previously treated advanced or metastatic clear cell renal cell carcinoma.

Subgroup results

Opdivo plus Yervoy and chemo at PD-L1 below 1%: Checkmate 9LA results?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

Comparisons

Does Opdivo improve survival vs docetaxel in previously treated NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)

Long-term results

What is 5-year survival with Opdivo in previously treated NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO IV monotherapy (Checkmate 057 and 017)